A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301).

MLA

Tolcher, Anthony, et al. “A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors (301).” Gynecologic Oncology, vol. 166, Aug. 2022, p. S158. EBSCOhost, https://doi.org/10.1016/S0090-8258(22)01523-2.

APA

Tolcher, A., Vandross, A., Johnson, M., Park, H., Scheffold, C., Li, J., Bekele, N., Uttamsingh, S., Faggioni, R., & Ulahannan, S. (2022). A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301). Gynecologic Oncology, 166, S158. https://doi.org/10.1016/S0090-8258(22)01523-2

Chicago

Tolcher, Anthony, Andrae Vandross, Melissa Johnson, Haeseong Park, Christian Scheffold, Jing Li, Neby Bekele, Shailaja Uttamsingh, Raffaella Faggioni, and Susanna Ulahannan. 2022. “A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors (301).” Gynecologic Oncology 166 (August): S158. doi:10.1016/S0090-8258(22)01523-2.